The asset was developed via ProBio’s biologics discovery and development operations and is directed against an oncology target.
ProBio is set to receive an upfront payment, alongside eligibility for potential payments tied to developmental and commercial milestones. Financial figures of the deal were not disclosed.
The agreement additionally entitles the company to receive royalties on future product sales generated by the candidate.
AbTis, a subsidiary of Dong-A ST, plans to incorporate the licensed antibody into its portfolio of bispecific antibody-drug conjugates (ADCs).
The company will apply its AbClick site-specific conjugation technology to develop the candidate into a next-generation ADC.
The AbClick linker platform enables controlled, site-specific antibody conjugation, designed to progress conjugate consistency and characteristics relative to conventional non-specific conjugation methods across oncology applications.
ProBio CEO Allen Guo said: “This agreement demonstrates the value of ProBio’s strategy to not only support our partners’ programmes, but also generate differentiated assets that can advance into innovative therapeutic development.
“By combining ProBio’s biologics discovery capabilities with AbTis’ site-specific ADC technology, we have the opportunity to accelerate the development of a promising oncology asset and create additional value for patients and our partners.”
The transaction aligns with ProBio’s role as a global contract research, development, and manufacturing organisation (CRDMO), providing partners with an integrated pathway that links scientific research directly with manufacturing capabilities.
Operating across biologics, cell therapy, and gene therapy, ProBio maintains scalable, good manufacturing practice (GMP)-compliant facilities designed to de-risk development schedules and shorten production timelines.
AbTis remains focused on advancing bioconjugate therapeutics, seeking to improve clinical outcomes for individuals treated for cancer and other serious diseases.